Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1067
Peer-review started: July 27, 2020
First decision: September 21, 2020
Revised: October 4, 2020
Accepted: October 26, 2020
Article in press: October 26, 2020
Published online: November 27, 2020
Processing time: 120 Days and 11.5 Hours
Gastric antral vascular ectasia (GAVE) is a well-recognized cause of gastrointestinal bleeding in cirrhotic patients. The etiology of GAVE remains unclear, although several humoral, autoimmune, mechanical stress, and pharmacological (proton pump inhibitor use) hypotheses have been described. Different treatment modalities have been proposed with varying results. Orthotopic liver transplantation (OLT), which is often recommended for patients with significant complications due to end-stage liver disease, has also been shown to be beneficial treatment for resolution of GAVE and associated anemia in a few small studies.
To evaluate the relation between GAVE and associated anemia and OLT.
To assess the impact of OLT on resolution of the natural course of GAVE and associated anemia.
A retrospective chart review was conducted of adult patient with GAVE who underwent liver transplant between September 2012 and September 2019. Demographics and other relevant findings, including hemoglobin levels, Model of End-stage Liver Disease-sodium score, GAVE presentation, and upper endoscopy findings before and after OLT were collected.
Sixteen patients were identified, all Caucasians and predominantly female (62.5%) with a mean age of 56.5 years. The most common etiology for cirrhosis was NASH (44%). All patients presented with anemia, with 50% presenting with overt bleed and required transfusions prior to transplant. Mean pre-OLT Hgb was 7.7, and the mean 12 mo post-OLT Hgb was 11.9 (P = 0.001). Anemia improved in 87.5% of patients (n = 14) within 6 to 12 mo after OLT and resolved completely in half of the patients. Post-OLT esophagogastroduodenoscopy was performed in 10 patients, and GAVE resolved entirely in 6 of those patients (60%).
Although GAVE and associated anemia completely resolved in the majority of our patients after liver transplantation, GAVE persisted in a few patients after transplant.
Large prospective studies are needed to better understand what factors may contribute to persistent GAVE post-liver transplant.